Immune Tolerance Network for safer, more effective immune therapies
Official title: Immune Tolerance Network
Funded at Benaroya Research Inst at Virginia Mason · NIH-11609234 · Data updated 2026-11-12
A nationwide network tests new immune therapies to help people with autoimmune diseases, allergies, and transplant patients reach better control of their immune system.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Benaroya Research Inst at Virginia Mason NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | February 1, 2014 |
| Project end | January 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $2,548,090 |
| NIH project number | 3UM1AI109565-13S5 |
| Project ID | NIH-11609234 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with autoimmune conditions, allergies, or transplant-related immune challenges who are eligible for immune tolerance therapies and willing to participate in trial activities.
✕Less likely to help
Individuals not experiencing immune-related disease or not meeting trial criteria may not benefit from these studies.
What this research studies
The program brings multiple clinical trials together with advanced lab analyses to study how immune tolerance works and how treatments change immune cells and genes. It aims to move promising tolerance therapies from the lab to real patient care by testing them in diverse diseases across immunology. Researchers partner with many clinical sites to run trials, collect data, and analyze immune responses to identify the most promising approaches for future use.
Why it matters
Potential benefit: If successful, the work could lead to safer, more effective treatments that prevent unwanted immune reactions and improve quality of life for patients with autoimmune diseases, allergies, and transplant recipients.
How similar studies have gone: Previous immune tolerance trials have informed therapy development, and this program builds on that foundation with broader disease applications and integrated immunology analyses.
Where this research is happening
-
Benaroya Research Inst at Virginia Mason
Seattle, United States Active
Researchers
- Principal investigator: Buckner, Jane Hoyt — Benaroya Research Inst at Virginia Mason
- Study coordinator: Buckner, Jane Hoyt
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.